Kojin Therapeutics

Many thanks to Brad Loncar of BiotechTV for catching up after a fortuitous meeting en route to Boston. From the MassBio studio, I shared with him the challenges of financing pre-IND companies and the need for creative structures and terms for early-stage investments. Venture investors are looking for differentiated, innovative opportunities based on cutting-edge science. To achieve this, we are going to recapitalize and restart Kojin Therapeutics to maximize shareholder value and build a strong syndicate of new and current investors. More to come. #venturecapital #ferroptosis #redox #lipidmetabolism #cancer #immunology #innovation #drugdiscovery #startup #boston #seaport Boston Business Journal

Our CEO, Harvey Berger, had an opportunity to discuss our progress in developing #ferroptosis medicines and financing future growth with Brad Loncar, the founder of BiotechTV. While our understanding of the underlying human biology is expanding exponentially, capital for pre-IND companies like Kojin Therapeutics is hard to access. However, given our team’s innovation and insights in the role of ferroptosis in cancer and immune & inflammatory diseases, we see a clear path forward to accelerate our drug-discovery initiatives into the clinic. #venturecapital #redox #lipidmetabolism #cancer #autoimmunedisease #smallmolecules MassBio

Our CEO, Harvey Berger, MD, was interviewed today by Brad Loncar, the founder of BiotechTV, at the MassBio Kendall Square podcast studio. They discussed the financing environment, #ferroptosis, innovation in biotech, and our company’s progress. Catch the video of the interview later this week. Kojin Therapeutics #cancer #immunology #lipidmetabolism #redox #biopharma #venturecapital

Building a new organization is driven by intense passion, vision, and dedication and is focused on shared goals, strategy, and respect. Teamwork means everyone’s viewpoints count, and new perspectives are welcomed. At Kojin Therapeutics, we chose a hard path forward – translating recent discoveries in complex human biology into new therapeutics. The outcome, however, is clear – medicines that for the first time target key nodes in the #ferroptosis pathway and modulate disease in a mechanism-specific way. Smart personalized medicine. Under the leadership of our ferroptosis pioneers, we are well along the way to achieving the goal of bringing ferroptosis inducers to patients worldwide. Our talented scientists are up for the challenge. #cancer #immunology #inflammation #redox #lipidmetabolism #biotech #biopharma #startup #venturecapital  Harvey Berger | Horst Hemmerle | Jennifer O'Neil | Hagop Youssoufian | Narayana Narasimhan | Wei-Sheng Huang | David Dalgarno | Sangeetha Palakurthi, Ph.D.  

Our Chairman and Chief Executive Officer, Harvey Berger, M.D., will be chairing the upcoming panel on accelerating drug discovery at the annual Longwood Healthcare Leaders #BostonCEO forum, to be held at the Mandarin Oriental Hotel, Boston, October 28-29, 2024. The panel will address how leading companies are translating complex human biology into new therapeutics, expediting the drug discovery process, innovating and identifying new technologies, targets, and medicines, expanding company portfolios, and leveraging partners’ expertise in discovery initiatives. Specific topics will include pan-KRAS inhibitors, localizing molecular glues, new uses of CRISPR, therapeutic options for modulating ferroptosis and cell-state, and new biological approaches to discovery. The two-day, industry-leading meeting, chaired by Christoph Westphal, focuses on a broad spectrum of topics affecting the biopharma ecosystem. Decision makers in the life sciences, including biotech and pharma CEOs, heads of research and development, leading academics, and investors will discuss some of the most important issues facing healthcare today. Information and registration: https://lnkd.in/eehfZ2xB.     Kestrel Therapeutics | Cullinan Therapeutics | Excision BioTherapeutics | Magnet Biomedicine | Longwood Fund | Kojin Therapeutics | Brian Safina | Frank Haluska | Daniel Dornbusch | Jennifer Michaelson #ferroptosis #redox #KRAS #molecularglues #CRISPR #drugdiscovery #cancer #immunology #infectiousdisease #platforms #innovation #smallmolecule #biopharma #biotech #boston

Under the leadership of our new Chairman and Chief Executive Officer, Harvey Berger, M.D., we have revamped our executive leadership and scientific teams and sharpened our R&D focus. As we accelerate our transition to a development-stage company, Harvey regularly underscores the exceptional talent and innovative mindset of our scientists in achieving our milestones and working together to develop transformative medicines. A bit of history -- the six medicines and diagnostics that were developed under his leadership by Centocor, ARIAD, and Medinol have thus far generated over $128 billion in global sales and are expected to top $145 billion over their lifespan. This points to a bright future for Kojin Therapeutics. #ferroptosis #redox #cancer #immunology #biotech #drugdiscovery #medicine #leadership #autoimmunity #cardiology #drugelutingstent #medicalinnovation #medtech #diagnostics #nuclearmedicine

A gifted Scotsman, David Dalgarno, D. Phil., joined Kojin Therapeutics early this year as Senior Vice President, Digital & Data Science and Technology. After graduating with two degrees from Oxford and completing a fellowship at Yale, David started an illustrious career in the biotech industry. At ARIAD, he set up one of the first two biotech-based high-field #NMR laboratories in the Cambridge area and promoted the early applications of NMR to structure-based drug design for over 20 years. Evolving as a technology and biophysics guru, he is always looking for new ways to apply novel approaches in AI/ML, computational sciences, and state-of-the-art instrumentation to accelerate drug discovery. Never one to rest on his laurels, he has re-engaged with his secondary school, Robert Gordon's College, to promote their #STEM initiatives. #ferroptosis #redox #lipidomics #drugdiscovery #biophysics #AI #machinelearning #datascience #structuralbiology

We welcome Hagop Youssoufian, M.D. as our Chief Medical Advisor and a member of our evolving leadership team. Hagop is a distinguished physician-scientist and drug-development professional with over 35-years of experience in academia and industry – including biotech and big pharma companies. He has overseen more than 100 INDs and 500 clinical trials involving new medicines for solid tumors and hematologic malignancies. He is setting in motion plans for biomarker-enriched clinical trials of our first #ferroptosis medicines. Although Hagop finds it difficult to accept the notion of spare time, he nevertheless manages to be a loud cheerleader for Manchester City F.C. and its winning culture in the English Premier League. #redox #cancer #immunology #clinicaltrials #precisionmedicine #precisiononcology #genetics #oncology #biotech #biomarkers

Our chief executive, Harvey Berger, is chairing the Accelerating Drug Discovery panel at the upcoming #BostonCEO Longwood Healthcare Leaders Conference. Learn about the approaches we and others are taking to make drug discovery more efficient and innovative.

Our Senior Vice President, Preclinical Development -- Narayana Narasimhan, Ph.D. -- started his academic career in chemistry, math, and statistics, and today is focused on the transition from the bench to in vivo studies, leading our assessment of the preclinical safety and efficacy of potential new ferroptosis medicines. Our “go-to” scientist for all aspects of preclinical development, Narasimhan (aka “Nachu”) and his team are gearing up for the start of IND-enabling studies of our first development candidate in 2025. He has traveled the world but especially loves the U.S. National Parks; he hopes to visit all of them and hike many of the most strenuous and challenging trails. #ferroptosis #redox #pharmacology #invivo #biotech #drugdevelopment #drugdiscovery #cancer #immunology